QuantHealth

Company Overview

Snapshot

Founded in June 2020 by Orr Inbar and Arnon Horev, QuantHealth operates with 51–200 employees. The company has raised $66.01 million across 6 funding rounds from 13 investors, with Qumra Capital leading a recent round.

Business overview

QuantHealth is an AI company focused on accelerating and de-risking drug development through patient-centric drug simulations. Its AI solution enables clinical development and operations teams to simulate clinical trials in thousands of variations within minutes, evaluating parameters for endpoint success, commercial viability, and protocol feasibility. The in-silico platform generates synthetic evidence for therapy performance across clinical phases, supporting trial planning, indication selection, drug repurposing, and in-licensing asset evaluation. The company's Large Healthcare Model (LHM) learns deep patient-drug interactions to drive high-resolution outcome models with 86% endpoint accuracy, serving the pharmaceutical and biotechnology industries within the Health Tech & Life Sciences sector.

Strategic signal

In April 2024, QuantHealth appointed esteemed pharmaceutical executives to its inaugural Advisory Board. This strategic move signals the company's commitment to leveraging deep industry expertise to guide its growth and product development, enhancing its credibility and market penetration within the pharmaceutical sector. For investors, this indicates a strengthening of leadership and strategic direction, potentially leading to accelerated adoption of its AI-driven clinical trial simulation solutions.

Company Intelligence Q&A

What was the outcome of the partnership between 4P-Pharma and QuantHealth?

In March 2022, 4P-Pharma and QuantHealth joined forces to conduct AI-based in-silico clinical trial simulations, aiming to advance drug development.